Melanoma has a high propensity to metastasise to the brain. Up to 50% of patients with stage IV disease will develop brain metastases during the course of their illness (25% of patients have them at initial diagnosis of stage IV) and these are associated with a poor prognosis, with a median overall survival (OS) of 2.8 to 4 months. Control of brain metastases is important since its progression often leads to deterioration in neurological function and quality of life and/or neurologic death.
This section covers the following:
- Role of systemic drug therapy in the management of advanced melanoma patient with brain metastases
- Surgical approach to brain metastases for patients with advanced melanoma
- Role of radiotherapy in the management of advanced melanoma patient with brain metastases
- Treatment approaches to brain metastases: Summary of recommendations
- Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012 Aug 15;118(16):4014-23 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/22180178.
- Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011 Apr 15;117(8):1687-96 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/20960525.
- Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004 Apr 1;22(7):1293-300 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/15051777.
- Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J, et al. Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. Br J Cancer 2011 Jun 7;104(12):1816-21 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/21610711.